Zobrazeno 1 - 10
of 29
pro vyhledávání: ''
Autor:
Manisha Palta, Kent J. Weinhold, Brian G. Czito, David M. Brizel, John S. Yi, April K.S. Salama, Christel Rushing, Douglas S. Tyler, Brent A. Hanks, Georgia M. Beasley, David S. Yoo, Paul J. Mosca, Kristen N. Linney, M. Angelica Selim, Chelsae Dumbauld, Katelyn N. Steadman, Walter T. Lee
Publikováno v:
Clin Cancer Res
Purpose:In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma.Patients and Methods:Twenty-
Autor:
Guanghui Gao, Zhe-Hai Wang, Jifeng Feng, Meijuan Huang, Xinmin Yu, Zhihua Liu, Caicun Zhou, Lihong Wu, Yina Wang, Ying Cheng, Jun Zhao, Yuan Chen, Zhiyong Ma, Weixia Li, Xiaoyan Lin, Shengxiang Ren, Kangsheng Gu, R. Guo, Jun Zhang, Quan Ren Wang, Xinfeng Yang, Gongyan Chen, Yu Yao, Jianxing He, Jianhua Chen, Jianhua Shi
Publikováno v:
Clinical Cancer Research. 27:1296-1304
Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T cells and reducing recruitment of tumor-associated macrophages. We hereby
Autor:
Chiara Cremolini, Axel Grothey, Jim Abraham, Donald A. Berry, David D. Halbert, Mohamed E. Salem, Michael J. Hall, Matthew J. Oberley, Anthony Helmstetter, Carlotta Antoniotti, W. Michael Korn, Anthony F. Shields, David Spetzler, John L. Marshall, Alfredo Falcone, Phillip Stafford, Daniel Magee, Joanne Xiu, Heinz-Josef Lenz, Alan P. Venook
Publikováno v:
Clinical Cancer Research. 27:1174-1183
Purpose: FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab is considered standard first-line treatment option for patients with metastatic colorectal cancer (mCRC). We developed and validated a molecular signature predictive of efficacy of
Autor:
Anthony Serritella, Bryan Peterson, Stephanie Moya, Yan Wang, Natalie Reizine, Joseph Thomas, Carol Tan, Katherine I. Zhou, Daniel V.T. Catenacci
Publikováno v:
Clin Cancer Res
Purpose: Intrapatient heterogeneity of programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) could influence their roles as predictive biomarkers for response to immune checkpoint inhi
Autor:
Meixia Chen, John E.J. Rasko, Qingming Yang, Liang Dong, Wenying Zhang, Jing Nie, Huitao Wu, Yang Liu, Weidong Han, Qian Mei, Xiang Li, Lu Shi, Yan Zhang, Jiejie Liu
Publikováno v:
Clinical Cancer Research. 26:4521-4530
Purpose: Patients with relapsed/refractory primary mediastinal B-cell lymphoma (rrPMBCL) represent a particularly challenging population to treat, with few life-saving treatment options in the context of a dismal prognosis. Patients and Methods: In t
Autor:
Naomi Fujioka, Junxuan Lu, Chengguo Xing, Katelyn M. Tessier, Sreekanth C. Narayanapillai, Qi Hu, Ramzi G. Salloum, Dorothy K. Hatsukami, Stephen S. Hecht, Yi Wang, Pramod Upadhyaya, Lori S Strayer, Richard L. Kingston
Publikováno v:
Cancer Prev Res (Phila)
Tobacco smoking is the primary risk factor for lung cancer, driven by the addictive nature of nicotine and the indisputable carcinogenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) as well as other compounds. The integration of lung ca
Autor:
Darrell R. Fisher, Ajay K. Gopal, Brenda M. Sandmaier, John M. Pagel, Robert S. Miyaoka, Ted Gooley, Damian J. Green, Joseph G. Rajendran, Leona Holmberg, Ryan D. Cassaday, Oliver W. Press
Publikováno v:
Clin Cancer Res
Purpose: External-beam radiation is the single most effective therapy for localized lymphoma. However, toxicity limits its use for multifocal disease. We evaluated CD45 as a therapeutic target for an antibody–radionuclide conjugate (ARC) for the tr
Autor:
Oladimeji Akinboro, Jamie S. Ostroff, Olatunde Ola, Oluseyi Balasire, Stanley Madu Nwabudike, Rawad Elias
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 28:2087-2094
Background: The prevalence of electronic cigarette (e-cigarette) use and its impact on smoking cessation among cancer survivors in the United States is largely unknown. We sought to estimate the prevalence of e-cigarette use and examine its associati
Autor:
Neeraj Lal, Riyue Bao, Sandra Ventorin Von Zeidler, Arun Khattri, Helen R Valentine, Albert N. Menezes, Jean-Baptiste Cazier, Hisham Mehanna, Tanguy Y. Seiwert, Maha Ibrahim, Steven P. Lee, Jonathan J Deeks, Lucinda Archer, Daniel A. Tennant, Andrew D Beggs, Christopher Bagnall, Margaret Hartley, Nikolaos Batis, Kalu U.E. Ogbureke, Baksho Kaul, Jill Brooks, Gary Middleton, Jennifer L. Bryant, Catharine M L West, Gordon B. Ryan, Rachel Spruce, Benjamin E. Willcox
Publikováno v:
Clinical Cancer Research. 25:5315-5328
Purpose: Intratumoral hypoxia and immunity have been correlated with patient outcome in various tumor settings. However, these factors are not currently considered for treatment selection in head and neck cancer (HNC) due to lack of validated biomark
Autor:
Ronald Sobecks, Melhem Solh, Baldeep Wirk, Joseph P. McGuirk, Zhen-Huan Hu, Kwang Woo Ahn, Yoshihiro Inamoto, Edward Agura, Ulrike Bacher, Miguel-Angel Perales, Usama Gergis, Harry C. Schouten, Joseph Pidala, Amer Beitinjaneh, Amelia Langston, Ran Reshef, Mohamed A. Kharfan-Dabaja, Robert S. Negrin, Saurabh Chhabra, David I. Marks, Virginia O. Volpe, Nilanjan Ghosh, Asad Bashey, Jennifer R. Brown, William J. Hogan, Ayman Saad, Wael Saber, Tamila L. Kindwall-Keller, Minoo Battiwalla, Brian T. Hill, Jan Cerny, Uday R. Popat, Oliver W. Press, Hillard M. Lazarus, Sid Ganguly, Jayesh Mehta, Attaphol Pawarode, Nakhle S. Saba, Taiga Nishihori, Edward A. Copelan, Jean A. Yared, Edwin P. Alyea, Jean-Yves Cahn, Steven M. Devine, Mazyar Shadman, Mahmoud Aljurf, Haesook T. Kim, Mohamed L. Sorror, Michael R. Grunwald, Robert Peter Gale, Richard F. Olsson, Richard A. Nash, Joseph H. Antin, Mehdi Hamadani, Stephen J. Forman, Gregory A. Hale, Bipin N. Savani, Matthew S. Davids, Sunita Nathan, Sergio Giralt, Joseph P. Uberti, Gerhard C. Hildebrandt
Publikováno v:
Clinical Cancer Research, 25(16), 5143-5155. American Association for Cancer Research Inc.
Purpose: To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT). Ex